Evaluating Body Mass Index and Platelet-to-Lymphocyte Ratio as Predictors of Survival in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Authors

  • Heba F. Taha, Lamiaa Mahmoud Mohammed Kamel, Almustafa Ahmed Abdulbadea, Ahmad Barakat Waley

Keywords:

Body Mass Index, Platelet-to-Lymphocyte Ratio, Diffuse Large B-Cell Lymphoma, R-CHOP

Abstract

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma,accounting for approximately 30–40% of adult cases worldwide. The standard first-line therapy, consisting of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), achieves high responserates; however, outcomes vary significantly among patients with similar clinical features. While the International Prognostic Index (IPI) remains a cornerstone for risk stratification, increasing attention has been given to host related biomarkers, such as body mass index (BMI) and inflammatory markers

References

Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040-2045.

Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842-858.

Downloads

Published

2024-06-20

How to Cite

Heba F. Taha, Lamiaa Mahmoud Mohammed Kamel, Almustafa Ahmed Abdulbadea, Ahmad Barakat Waley. (2024). Evaluating Body Mass Index and Platelet-to-Lymphocyte Ratio as Predictors of Survival in Diffuse Large B-Cell Lymphoma Treated with R-CHOP . Journal of Computational Analysis and Applications (JoCAAA), 33(06), 2686–2701. Retrieved from https://eudoxuspress.com/index.php/pub/article/view/3576

Issue

Vol. 33 No. 06 (2024): JOCAAA

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.